Pilulka Lekarny AS (XPRA:PINK) Stock Based Compensation: Kč0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPRA:PINK Pilulka Lekarny AS XPRA:PINK
50 GF Score
Price Kč110.00
GF Value Kč111.56
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Pilulka Lekarny AS Stock Based Compensation?

Pilulka Lekarny AS XPRA:PINK 50 Stock Based Compensation is Kč0 Mil as of Dec. 2025. GuruFocus rates XPRA:PINK with a GF Score™ of 50/100 and a GF Value™ of Kč111.56 (Fairly Valued). The stock has 6 warning signs investors should review.

Pilulka Lekarny AS's Stock Based Compensation for the six months ended in Dec. 2025 was Kč0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was Kč0 Mil.

Pilulka Lekarny AS Stock Based Compensation Related Terms

Pilulka Lekarny AS Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pilulka Lekarny AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pilulka Lekarny AS Stock Based Compensation Chart

Pilulka Lekarny AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pilulka Lekarny AS Semi-Annual Data
Dec20 Dec21 Dec22 Dec23 Jun24 Dec24 Dec25
Stock Based Compensation Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XPRA:PINK
50GF Score
Pilulka Lekarny AS XPRA:PINK
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pilulka Lekarny AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč0 Mil.

What does a Stock Based Compensation of Kč0 Mil mean?
Pilulka Lekarny AS (XPRA:PINK) has a Stock Based Compensation of Kč0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pilulka Lekarny AS and its competitors.
Is Pilulka Lekarny AS's Stock Based Compensation too high?
Pilulka Lekarny AS's current Stock Based Compensation is Kč0 Mil. Overall, Pilulka Lekarny AS has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Stock Based Compensation compare to competitors?
Pilulka Lekarny AS's Stock Based Compensation of Kč0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Healthcare Providers & Services company?
A good Stock Based Compensation depends on the Healthcare Providers & Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pilulka Lekarny AS and its competitors. Pilulka Lekarny AS's current Stock Based Compensation is Kč0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč111.56, compared to a current price of Kč110.00 — trading 1.4% below its estimated fair value. The current Stock Based Compensation is Kč0 Mil. Pilulka Lekarny AS's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Stock Based Compensation is Kč0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?

Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be undervalued. The current stock price of Kč110.00 is trading 1.4% below its estimated GF Value™ of Kč111.56. GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.

Key valuation signals for XPRA:PINK:

  • Stock Based Compensation: Kč0 Mil
  • GF Value™: Kč111.56 vs. price of Kč110.00 (1.4% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pilulka Lekarny AS Business Description

Address Drahobejlova 1073/36, Prague, CZE, 190 00
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
50GF Score

Get the complete analysis for XPRA:PINK

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Kč110.00
Price
Kč111.56
GF Value